From August 2017 through July 2018, the FDA approved 14 new anticancer therapeutics. These included nine molecularly targeted therapeutics, part of the new wave of precision medicines, as well as two targeted forms of radiotherapy and two new CAR T-cell therapies. There are preclinical studies of vaccines that target oncogenes (early genetic changes that initiate […]
↧